surviv patient poor-prognosi malign melanoma adjuv levamisol phase iii studi nation cancer institut canada clinic trial group five forty-thre patient malign melanoma signific risk recurr diseas studi group group levamisol mg/kg consecut day year second group bacillu calmette-guerin bcg year third group cours bcg levamisol year fourth group underw clinic assess frequenc treatment group median durat follow-up year percentag reduct death rate recurr rate treatment group control group cox proport hazard model age sex stage covari patient levamisol reduct death rate recurr rate patient treatment fifty-f patient levamisol earli gastrointestin intoler arthralgia myalgia fever immun leukopenia patient bcg levamisol reduct death rate reduct recurr rate patient bcg reduct death rate increas recurr rate control group degre improv patient levamisol suffici magnitud investig dose levamisol adjuv treatment patient melanoma 